SUNNIFORECAST trial design supported by real-world data in papillary renal cell carcinoma

We read with interest the recent report from the SUNNIFORESCAST trial (Bergmann et al. Ann Oncol. 2025), which compared ipilimumab–nivolumab with standard-of-care therapies in untreated non-clear cell renal cell carcinoma (nccRCC).1 We commend the authors for conducting a much-needed randomized trial in this understudied population and agree with their choice of control arm, given the absence of a universally accepted…